IMO HEXO did a reverse split to stay listed in Nasdaq.
No cannabis bill in US next year would likely see HEXO delisted.
Tilray would do well buying Hexo at this discount.
The research into Grow Ops, Terpenes, CBD, preroll and strains created by Redecan could be acquired at pennies to the dollar.